Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00780234 · ClinicalTrials.gov registry record · Phase 2
Pioglitazone for Lung Cancer Chemoprevention
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00780234: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT00780234 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 92 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00780234, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is a chemoprevention trial evaluating the diabetic agent pioglitazone. Non-diabetic subjects at risk for lung cancer (based on smoking history, lung function testing, and atypical cells in a sputum sample) receive either placebo or pioglitazone and have chest computerized tomography (CAT) scans and examinations of their airways with a bronchoscope at the start of the trial and after 6 months on treatment. Compensation will be provided to the subject after completing the trial.
Interventions
- PROCEDURE fluorescence bronchoscopy
- PROCEDURE quantitative high resolution CT scan
- DRUG PIOGLITAZONE VS. PLACEBO 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2009-08 |
| Est. Completion | 2017-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00780234
The ClinicalTrials.gov registry entry for NCT00780234 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which fluorescence bronchoscopy is the first listed.
NCT00780234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00780234 about?
NCT00780234 is a clinical study titled "Pioglitazone for Lung Cancer Chemoprevention". This is a chemoprevention trial evaluating the diabetic agent pioglitazone. Non-diabetic subjects at risk for lung cancer (based on smoking history, lung function testing, and atypical cells in a sputum sample) receive either placebo or pioglitazone and have chest computerized tomography (CAT) scans...
What is the current status of trial NCT00780234?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2009-08. Estimated completion is 2017-08.
What interventions are being tested in trial NCT00780234?
The interventions under investigation include: fluorescence bronchoscopy (PROCEDURE), quantitative high resolution CT scan (PROCEDURE), PIOGLITAZONE VS. PLACEBO 30 mg (DRUG).
Who is sponsoring clinical trial NCT00780234?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.